VQ-201
Asset
Antagonizes C5aR1 to reduce pathogenic complement-mediated inflammation.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- C5AR1
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Inflammatory disorder
Preclinical, vanquabio.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.